A Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs E 2307 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 15 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Jun 2015 Planned number of patients changed from 64 to 24, as reported by ClinicalTrials.gov record.
    • 05 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Feb 2015, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top